SAN DIEGO, July 17, 2025 /PRNewswire/ -- How can actionable, Six Sigma insights improve lab performance? In a featured session at the Association for Diagnostics & Laboratory Medicine (ADLM) meeting, QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho") and a panel of experts will share how QuidelOrtho's Six Sigma tools and real lab data can drive quality outcomes.
ADLM Session Details:
Session Title: | Real Labs, Real Decisions with Actionable Six Sigma Metrics |
When: | Tuesday, July 29, 2025 |
Where: | McCormick Convention Center Chicago, IL Exhibit Hall, Theater 1 |
Time: | 2:45 p.m. – 3:45 p.m. CT |
Registration: | Space is limited. ADLM attendees can register for the session using |
Real Labs, Real Decisions With Actionable Six Sigma Metrics Panelists:
Dr. Jared Jaeger
Clinical Science Liaison
QuidelOrtho
Moderator
Dr. Bremansu Osa-Andrews
Medical Director of Clinical
Chemistry and Clinical Assistant Professor
University of Florida PathLab
Gilles Attipoe
Director of Laboratory Services
St. Peter's University Hospital
Angela Armato
Core Lab Manager
United Health Services and UHS Hospitals
To learn more about Six Sigma and the value of using real-world data listen to "Sigma Metrics and the Value of Real World Evidence." In this podcast, QuidelOrtho data scientist Johanna Miller discusses how Six Sigma metrics are being adapted for the clinical laboratory.
Unable to attend ADLM? Register to watch a recording of the session: https://www2.na-ma.quidelortho.com/25-adlm-workshop-subscribe.
About QuidelOrtho
QuidelOrtho Corporation (Nasdaq: QDEL) is a world leader in in vitro diagnostics, developing and manufacturing intelligent solutions that transform data into understanding and action for more people in more places every day.
Offering industry-leading expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine, bringing fast, accurate and reliable diagnostics when and where they are needed–from home to hospital, lab to clinic.
Building on its long history of innovation, QuidelOrtho works with global healthcare customers to advance diagnostics, where insights and solutions seamlessly connect, illuminating a clearer path for informed decisions.
Investor Contact: Juliet Cunningham Vice President, Investor Relations This email address is being protected from spambots. You need JavaScript enabled to view it. | Media Contact: D. Nikki Wheeler Senior Director, Corporate Communications This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$27.90 |
| Daily Change: | 2.24 8.73 |
| Daily Volume: | 1,511,346 |
| Market Cap: | US$1.890B |
August 19, 2025 August 13, 2025 August 05, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
